Deals: Page 16
-
SciePro via Getty Images
Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug
The deal hands $275 million upfront to Cullinan, whose medicine is being developed for a genetic driver of lung tumors that's become a top target for drugmakers.
By Kristin Jensen • May 12, 2022 -
Dan Kitwood via Getty Images
Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs
The deal, which hands Pfizer full rights to the biotech's fast-selling Nurtec ODT, could provide a much needed spark for the sector after months of stock market declines.
By Ben Fidler , Jacob Bell • Updated May 10, 2022 -
Permission granted by Biogen
Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan
Though executives claimed that inking deals and derisking research programs are priorities, analysts questioned whether any meaningful strategic changes will occur in the near term.
By Jacob Bell • May 4, 2022 -
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
A cancer biotech attracts another deep-pocketed partner in Gilead
Following rivals like Bristol Myers Squibb and Merck, Gilead has linked up with Dragonfly Therapeutics to develop new immunotherapies based on "natural killer cell engagers."
By Jacob Bell • May 2, 2022 -
A promising cancer drug leads Regeneron to reconsider its aversion to M&A
Regeneron has agreed to purchase Checkmate Pharmaceuticals for $250 million, the first acquisition of a publicly traded company in the biotech's nearly 35-year history.
By Jacob Bell • April 19, 2022 -
Brian Tucker/BioPharma Dive
Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B
Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.
By Jacob Bell • April 13, 2022 -
Warren Little via Getty Images
GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history
The British pharma is buying into the potential of a medicine meant to treat the anemia often associated with myelofibrosis, a complication that isn't adequately addressed by current therapies.
By Ben Fidler , Ned Pagliarulo • April 13, 2022 -
Maddie Meyer via Getty Images
Pfizer, Moderna name new finance chiefs amid surging revenue
Pfizer is bringing in former Lowe's and CVS Health executive David Denton, while Moderna hired Jorge Gomez, previously CFO at Cardinal Health. Both take the reins as their new companies face strategic questions.
By Jonathan Gardner • April 11, 2022 -
Dan Kitwood via Getty Images
Pfizer buys a private biotech and its RSV drug research
The pharma company will add experimental RSV treatments to its pipeline through the deal, which is worth up to $525 million.
By Kristin Jensen • April 7, 2022 -
Getty / Edited by BioPharma Dive
Regeneron, in search of an eye gene therapy, turns to a young biotech
Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease.
By Jacob Bell • April 6, 2022 -
Courtesy of Sanofi
Sanofi pays IGM $150M, continuing search for better antibody drugs
The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines.
By Ben Fidler • March 29, 2022 -
Spencer Platt via Getty Images
Pfizer claims study success for drug key to Arena buyout
Etrasimod, the basis of the $7 billion acquisition and a potential rival to Bristol Myers Squibb's Zeposia, has cleared the first of two trials in ulcerative colitis.
By Kristin Jensen • March 23, 2022 -
AscentXmedia via Getty Images
GSK partners with LifeMine as startups advance plans to make drugs from fungi
The deal, announced alongside a $175 million round, makes biotech entrepreneur Greg Verdine's startup the most well-funded among an emerging group of companies searching for drugs in fungal DNA.
By Ben Fidler • March 23, 2022 -
Permission granted by Biogen
Biogen and its partner rework terms of Aduhelm deal amid slow sales
Instead of sharing global profits and losses, Eisai will receive royalties tied to net sales of the Alzheimer's drug. Biogen, meanwhile, said the amended deal should make it easier to "address market developments."
By Jacob Bell • March 15, 2022 -
Courtesy of Sanofi
Sanofi lures Blackstone backing in unusual deal for multiple myeloma drug
Rather than fund development of a more convenient version of its blood cancer drug Sarclisa on its own, Sanofi has instead turned to Blackstone, which has fast become one of the sector's more active investors.
By Kristin Jensen • March 15, 2022 -
AbbVie keeps up dealmaking pace in neuroscience
On the heels of its Syndesi acquisition, the company has announced an agreement with Gedeon Richter focused on researching and developing new dopamine-regulating drugs for neuropsychiatric diseases.
By Jacob Bell • March 11, 2022 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
After slower-than-expected review, Pfizer and Arena close buyout deal
Pfizer officially closed its $7 billion acquisition of Arena Pharmaceuticals on Friday without needing to divest any assets.
By Jacob Bell • Updated March 11, 2022 -
Getty / Edited by BioPharma Dive
Novartis turns to Voyager for nervous system gene therapies
The deal, which carries a $54 million upfront payment, could give Novartis access to as many as five of Voyager's capsids, which would be used to develop gene therapies for the central nervous system.
By Jacob Bell • March 8, 2022 -
Bluebird's CFO resigns as cash woes raise doubts about its future
The gene therapy developer's top financial executive, Gina Consylman, is stepping down amid concerns the company needs to raise additional cash to survive for more than a year.
By Jonathan Gardner • March 7, 2022 -
Courtesy of Biocon
Viatris sells off biosimilars business in $3.3B deal
The sale to Biocon represents the first major step Viatris has taken to reshape itself, following a strategic review that took place throughout 2021.
By Jacob Bell • Feb. 28, 2022 -
Biohaven stocks up on experimental drugs with new acquisition, licensing deal
Separate agreements with Channel Biosciences and Bristol Myers Squibb give Biohaven access to experimental treatments for spinal muscular atrophy and for epilepsy.
By Jacob Bell • Feb. 25, 2022 -
James Thew/stock.adobe.com
Sponsored by TrialCardCopay accumulators, maximizers and the CMS best price rule: What you need to know now
Copay accumulators, maximizers and best price concerns dominated the copay assistance landscape in 2021. Here is an update on the most prominent developments in this area over the last six months.
By Jason Zemcik, Vice President, Patient Affordability, TrialCard • Feb. 22, 2022 -
Pressed by Wall Street, pharma executives signal openness to M&A
Despite tumbling biotech valuations, however, several said they still prefer smaller-sized "bolt-on" deals to larger, potentially more disruptive, transactions.
By Ned Pagliarulo • Feb. 7, 2022 -
Courtesy of Intellia Therapeutics
Intellia, expanding in gene editing, buys startup Rewrite for $45M
Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.
By Ned Pagliarulo • Feb. 3, 2022 -
Biogen, facing pressure on all sides, sells stake in biosimilars business
The biotech will sell the roughly 50% stake it holds in a biosimilars joint venture to Samsung Biologics for as much as $2.3 billion — cash that analysts expect the drugmaker to invest in M&A.
By Ned Pagliarulo , Jacob Bell • Jan. 28, 2022
Previous
